secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004595
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports $227.8M cash, updates on VMT-α-NET and VMT01 trials
--------------------------------------------------------------------------------

- Preliminary unaudited cash, equivalents and ST investments: $227.8M as of Dec 31, 2024, funding operations into late 2026.
- VMT-α-NET: 18 patients dosed in Cohort 2; data submitted to FDA; poster at ASCO-GI Jan 2025.
- VMT01: SMC recommends 1.5 mCi dose as monotherapy and with nivolumab; both cohorts open for enrollment.
- PSV359 IND filed late 2024; site activation underway, enrollment potentially mid-2025.
- Four additional novel assets planned for first-in-human imaging in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025004595/0000950170-25-004595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025004595/catx-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer